Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2002, Issue S1


Scott-Manno C
Gene Therapy for Hemophilia
Gac Med Mex 2002; 138 (S1)

Language: Español
References: 4
Page: 7-9
PDF: 29.36 Kb.


Full text




Text Extraction

A gene therapy or gene transfer approach to treatment of severe hemophilia has several attractive features. First, modest transgene expression resulting in small increases in the level of circulating F. VIII or F. IX levels would likely improve the clinical course of severe disease. The decreased bleeding observed in patients with moderate hemophilia (1–5% F. VIII or F. IX) or in those on prophylaxis regimens demonstrates this principle. Second, over-expression of the transgene product would be unlikely to result in hard to the patient. Finally, several animal models of hemophilia exist making the possibility of accurate pre-clinical experimentation a feasible enterprise.


Key words: No keywords


REFERENCIAS

  1. Herzog RW, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med 1999;5:56.

  2. Kay M, Manno C, Ragni M, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genet 2000;24:257.

  3. Roth DA, Tawa NE, O’Brien J, et al. Nonviral gene transfer of the gene encoding blood coagulation factor VIII in patients with severe hemophilia A. New Eng J Med 2001;344(23)1735.

  4. Wang L, Nicholas T, Read M, et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Molec Ther 2000;1:154.






>Journals >Gaceta Médica de México >Year 2002, Issue S1
 

· Journal Index 
· Links 






       
Copyright 2019